ELAN CORPORATION PLC ADR
Sector: Drug Delivery
Latest Quote @ Thu May 5 11:58:28 (15 min delayed)
Last Day's Data
Elan Corporation, plc engages in the discovery, development, manufacture, and marketing of advanced therapies in autoimmune diseases, such as pain and neurodegenerative diseases. The company operates in two segments, Biopharmaceuticals, and Global Services and Operations. The Biopharmaceuticals segment engages in biopharmaceutical research, development, and commercialization activities, which include the discovery and development of products in the therapeutic areas of neurology, autoimmune diseases, and pain. Its pharmaceutical commercial activities consists of the marketing of neurology/pain management products, including Myobloc that acts at the neuromuscular junction to produce flaccid paralysis; Zanaflex, which is used in the treatment of partial epileptic seizures in adults; and Frova that is used as an antimigraine therapy. This segment also markets various hospital products, such as Maxipime, an antibiotic that is used to treat patients with infections; and Azactam, which is used to treat pneumonia, post surgical infections, and septicemia. The Global Services and Operations segment focuses on product development and manufacturing to provide drug delivery technologies for the pharmaceutical industry. The company sells its pharmaceutical products primarily to drug wholesalers; and drug delivery products for licensees and distributors in the United States, the United Kingdom, and Ireland. Elan has collaboration agreement with Wyeth. The company was incorporated in 1969 and is headquartered in Dublin, Ireland.